Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT

Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT

Background and purpose: Prognosis of locally advanced non-small cell lung cancer remains poor despite chemoradiation. This planning study evaluated a stereotactic boost after concurrent chemoradiotherapy (30 × 2 Gy) to improve local control. The maximum achievable boost directed to radioresistant pr...

Full description

Bibliographic Details
Main Authors:	Tineke W.H. Meijer, Robin Wijsman, Edwin A. Usmanij, Olga C.J. Schuurbiers, Peter van Kollenburg, Liza Bouwmans, Johan Bussink, Lioe-Fee de Geus-Oei
Format:	Article
Language:	English
Published:	Elsevier 2018-07-01
Series:	Physics and Imaging in Radiation Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405631618300113

Similar Items

18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
by: Sara Carvalho, et al.
Published: (2018-01-01)

Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients
by: Govaert Stephanie LA, et al.
Published: (2012-09-01)

The Influence of the Exclusion of Central Necrosis on [<sup>18</sup>F]FDG PET Radiomic Analysis
by: Wyanne A. Noortman, et al.
Published: (2021-07-01)

Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy
by: Shiro Watanabe, et al.
Published: (2019-12-01)

Adding the temporal domain to PET radiomic features.
by: Wyanne A Noortman, et al.
Published: (2020-01-01)

Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
by: Sara Ramella, et al.
Published: (2013-01-01)

Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes
by: Tineke W.H. Meijer, et al.
Published: (2019-12-01)

A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus
by: Rajanigandha Tudu
Published: (2020-01-01)

The Value of 18F-FDG PET in Predicting the Prognosis of NSCLC
by: Yuzhou WANG, et al.
Published: (2009-05-01)

Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC.
by: Ranran Li, et al.
Published: (2017-01-01)

Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma
by: Esther M. M. Smeets, et al.
Published: (2019-03-01)

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
by: Tae Hoon Lee, et al.
Published: (2021-08-01)

Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma
by: Steven N. Seyedin, et al.
Published: (2020-07-01)

Evaluation of FDG-PET/CT Use in Children with Suspected Infection or Inflammation
by: Fabienne G. Ropers, et al.
Published: (2020-09-01)

Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma
by: Nikhil T. Sebastian, et al.
Published: (2019-11-01)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
by: John M. David, MD, et al.
Published: (2019-10-01)

A phase I study of dasatinib with concurrent chemoradiation for stage III non small cell lung cancer (NSCLC)
by: Howard eSafran, et al.
Published: (2012-05-01)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
by: Nappi Antonio, et al.
Published: (2015-12-01)

A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation
by: Yimin Li, et al.
Published: (2020-10-01)

Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases
by: Antonio Pontoriero MD, et al.
Published: (2020-04-01)

Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)
by: Alessandra Arcelli, et al.
Published: (2020-11-01)

Chemoradiation of pancreatic carcinoma
by: Erdinç Nayır, et al.
Published: (2016-08-01)

Chemoradiation for Olfactory Neuroblastoma
by: Sheun-Ru Yang, et al.
Published: (2015-03-01)

Surgical Resection Versus Stereotactic Body Radiation Therapy for Stage I NSCLC: Can Randomized Trials Provide the Solution?
by: Melanie P. Subramanian, et al.
Published: (2018-09-01)

Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
by: K. M. Kraus, et al.
Published: (2021-03-01)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
by: Ryan S. Youland, MD, et al.
Published: (2017-04-01)

Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature
by: Kaoru Kaseda
Published: (2020-08-01)

Impact of 18F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC
by: Akram Al-Ibraheem, et al.
Published: (2021-03-01)

Individualized threshold for tumor segmentation in 18F-FDG PET/CT imaging: The key for response evaluation of neoadjuvant chemoradiation therapy in patients with rectal cancer?
by: Theara C. Fagundes, et al.

Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F–FDG-PET-CT and/or diffusion-weighted MRI
by: Marjolein JE Greuter, et al.
Published: (2017-04-01)

Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
by: Daniel Dejaco, et al.
Published: (2020-09-01)

Dosimetric comparison of different algorithms in stereotactic body radiation therapy (SBRT) plan for non-small cell lung cancer (NSCLC)
by: Zhang J, et al.
Published: (2019-08-01)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01)

Concurrent chemoradiation for vaginal cancer.
by: David T Miyamoto, et al.
Published: (2013-01-01)

Chemoradiation in advanced vulval carcinoma
by: Rogers, Linda Joy
Published: (2014)

The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study
by: Solanki Abhishek A, et al.
Published: (2012-12-01)

Cost‐effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus
by: Jonathan Salcedo, et al.
Published: (2020-01-01)

Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.
by: Shaolei Li, et al.
Published: (2013-01-01)

18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
by: Florent L. Besson, et al.
Published: (2020-07-01)

Stereotactic body radiotherapy for pelvic boost in gynecological cancer patients with local recurrence or unsuitable for intracavitary brachytherapy
by: Hsin-Yi Cheng, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_7m77dtjdd9b3uv1kraajo86h6d